Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial

BACKGROUND: In the CheckMate-141 trial, nivolumab conferred a survival benefit in patients with recurrent or metastatic refractory squamous cell carcinoma (SCC) head and neck cancer (HNC). Here, we examined the efficacy of nivolumab in patients with histological subtypes or primary sites of HNC not...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Manag Res
Huvudupphovsmän: Sato, Yasuyoshi, Fukuda, Naoki, Wang, Xiaofei, Urasaki, Tetsuya, Ohmoto, Akihiro, Nakano, Kenji, Yunokawa, Mayu, Ono, Makiko, Sato, Yukiko, Mitani, Hiroki, Tomomatsu, Junichi, Takahashi, Shunji
Materialtyp: Artigo
Språk:Inglês
Publicerad: Dove 2020
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280058/
https://ncbi.nlm.nih.gov/pubmed/32581587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S249393
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk